Ausgabe 5/2009
Inhalt (12 Artikel)
Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells
Astrid Bernhaus, Maria Ozsvar-Kozma, Philipp Saiko, Margit Jaschke, Andreas Lackner, Michael Grusch, Zsuzsanna Horvath, Sibylle Madlener, Georg Krupitza, Norbert Handler, Thomas Erker, Walter Jaeger, Monika Fritzer-Szekeres, Thomas Szekeres
Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients
Daniel Laryea, Anders Isaksson, Colin W. Wright, Rolf Larsson, Peter Nygren
Artemisinin reduces human melanoma cell migration by down-regulating αVβ3 integrin and reducing metalloproteinase 2 production
Elisabetta Buommino, Adone Baroni, Nunzia Canozo, Marcella Petrazzuolo, Rosario Nicoletti, Antonio Vozza, Maria Antonietta Tufano
Amino acetate functionalized Schiff base organotin(IV) complexes as anticancer drugs: synthesis, structural characterization, and in vitro cytotoxicity studies
Tushar S. Basu Baul, Smita Basu, Dick de Vos, Anthony Linden
Mixed steroidal tetraoxanes induce apoptotic cell death in tumor cells
Željko Žižak, Zorica Juranić, Dejan Opsenica, Bogdan A. Šolaja
Extracts of marine sponge Polymastia janeirensis induce oxidative cell death through a caspase-9 apoptotic pathway in human U138MG glioma cell line
Mario Luiz Conte da Frota Jr., Elizandra Braganhol, Andrés Delgado Canedo, Fabio Klamt, Miriam Anders Apel, Beatriz Mothes, Cléa Lerner, Ana Maria Oliveira Battastini, Amélia Teresinha Henriques, José Cláudio Fonseca Moreira
Protective role of Withaferin-A on immunoexpression of p53 and bcl-2 in 7,12-dimethylbenz(a)anthracene-induced experimental oral carcinogenesis
Kuppusamy Panjamurthy, Shanmugam Manoharan, Madhavan Ramados Nirmal, Lakshmanan Vellaichamy
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
Sharon L. Sanborn, Joseph Gibbons, Smitha Krishnamurthi, Joanna M. Brell, Afshin Dowlati, Joseph A. Bokar, Charles Nock, Nancy Horvath, Jacob Bako, Scot C. Remick, Matthew M. Cooney
A phase I study of an oral simulated FOLFOX with high dose capecitabine
D. Mulkerin, N. K. LoConte, K. D. Holen, J. P. Thomas, D. Alberti, R. Marnocha, J. Kolesar, J. Eickhoff, K. Oliver, C. Feierabend, G. Wilding
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Robert P. Whitehead, Cathryn Rankin, Paulo M. G. Hoff, Philip J. Gold, Kevin G. Billingsley, Robert A. Chapman, Lucas Wong, John H. Ward, James L. Abbruzzese, Charles D. Blanke
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
Lawrence E. Garbo, Patrick J. Flynn, Margaret A. MacRae, Mary A. Rauch, Yunfei Wang, Kathryn S. Kolibaba
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma
Jérôme Fayette, Nicolas Penel, Christine Chevreau, Jean-Yves Blay, Didier Cupissol, Antoine Thyss, Cécile Guillemet, Maria Rios, Frédéric Rolland, Pierre Fargeot, Jacques Olivier Bay, Simone Mathoulin-Pelissier, Jean Michel Coindre, Binh Bui-Nguyen